micro-community-banner
Profile Image
  • Add Media
  • Saved

1yr
American Heart Association Scientific Sessions

The American Heart Association (AHA) will be hosting its annual scientific sessions at the McCormick Place Convention Center in Chicago from Nov. 16 to 18, 2024. This conference will focus on the latest innovations for scientists, clinicians, researchers, and other health care professionals interested in cardiovascular disease.

We will be covering the event for you, so stay tuned for reports with highlights and a wrap-up of the conference. Click above to access some of the highlights that caught our attention.

  • Saved

1yr
Management of triglycerides, non-high density lipoprotein cholesterol and high density lipoprotein cholesterol - PubMed

Management of triglycerides, non-high density lipoprotein cholesterol and high density lipoprotein cholesterol - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37979723/

Dyslipidaemia characterised by elevated total cholesterol/LDL-C, triglyceride or both or decreased HDL-C is an important risk factor for the development of ASCVD. Atherogenic dyslipidaemia characterised by high TG, low HDL-C...

Dyslipidaemia increases ASCVD risk, particularly in Asian Indians. Management includes lifestyle changes and pharmacotherapy for severe cases. Non-HDL-C is a better ASCVD risk marker than HDL-C, which lacks proven causality.

Profile Image
  • Saved

1yr
Role of PCSK9 inhibitors in the management of dyslipidaemia - PubMed

Role of PCSK9 inhibitors in the management of dyslipidaemia - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38195006/

Proprotein convertase subtilisin kexin9 (PCSK9) inhibitors are novel agents that lower LDL cholesterol and reduce cardio-vascular event rate. Being expensive, these agents are reserved for those with high risk or...

PCSK9 inhibitors lower LDL cholesterol and cardiovascular event rates, reserved for high-risk patients with inadequate responses to statins and ezetimibe or those intolerant to statins due to high cost.

Profile Image
  • Saved

1yr
Evolution of More Aggressive LDL-Cholesterol Targets and Therapies for Cardiovascular Disease Prevention - PubMed

Evolution of More Aggressive LDL-Cholesterol Targets and Therapies for Cardiovascular Disease Prevention - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38068483/

Over the last half-century, discussions on the exact targets for low-density lipoprotein cholesterol (LDL-C) reduction have evolved towards a more aggressive approach with lower LDL-C targets, particularly for high-risk patients...

This paper reviews the evolution of LDL-C targets in lipid management, highlighting the efficacy of statins and newer therapies in reducing ASCVD risk and advocating for lower LDL-C goals.

Profile Image
  • Saved

1yr
Bempedoic Acid: Lipid Lowering for Cardiovascular Disease Prevention - PubMed

Bempedoic Acid: Lipid Lowering for Cardiovascular Disease Prevention - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38419721/

The management of low-density lipoprotein cholesterol (LDL-C) levels is a central strategy for the prevention of atherosclerotic cardiovascular disease. Current United States (2018 American Heart Association/American College of Cardiology/Multisociety) and...

Bempedoic acid effectively lowers LDL-C and reduces major cardiovascular events in high-risk patients with statin intolerance, showing significant benefits while having fewer myalgia and diabetes events compared to placebo.

Profile Image